Successful simultaneous kidney-pancreas transplantation from extreme donors

Transplant Proc. 2005 Oct;37(8):3535-7. doi: 10.1016/j.transproceed.2005.09.060.

Abstract

The purpose of this study was to retrospectively review our experience with "extreme" pancreas donors compared to conventional (CONV) donors.

Methods: "Extreme" (EX) pancreas donors were defined as deceased donors (DDs) age >50 years, <8 years, donation after cardiac death (DCD), and targeted for organ discard.

Results: From January 2002 through January 2005, we performed 40 simultaneous kidney-pancreas transplants (SKPT) with Thymoglobulin induction, including 9 (22.5%) from EX and 31 from CONV DDs. Mean DD age was higher in EX DD (41.2 years EX vs 26.0 CONV, P < .05), but mean recipient age and cold ischemia times did not differ between groups. With a mean follow-up of 16.8 months in the EX DD group, patient and kidney graft survival rates are both 100%, and the pancreas graft survival rate is 89%. With a mean follow-up of 21.7 months in the CONV DD group, patient and kidney graft survival rates are both 93.5% and the pancreas graft survival rate is 77.4%. All patients with surviving grafts exhibited good initial (1 case of delayed kidney graft function in a CONV DD) and stable long-term kidney and pancreas graft function. Mean length of initial hospital stay and the incidences of acute rejection, readmissions, operative complications, and infections were similar between groups.

Conclusions: The results of this study suggest that the limits of donor acceptability continue to evolve as excellent outcomes can be achieved in SKPTs from selected EX DDs.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Antilymphocyte Serum / therapeutic use*
  • Child
  • Graft Rejection / epidemiology
  • Graft Survival
  • Heart Diseases / mortality
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology
  • Kidney Transplantation / physiology*
  • Middle Aged
  • Pancreas Transplantation / immunology
  • Pancreas Transplantation / physiology*
  • Postoperative Complications / epidemiology
  • Tissue Donors / statistics & numerical data*
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents